Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03773172 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03773172: Clinical Trial Phase 2 study, sponsored by Columbia University.
NCT03773172 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03773172, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100) lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).
Primary Outcome
FCR is the rate of synthesis and clearance of soluble lipoprotein B in participants per day.
Interventions
- DRUG Placebo
- DRUG MEDI6012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Why NCT03773172 stopped before completion
NCT03773172 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03773172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03773172 about?
NCT03773172 is a clinical study titled "Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism". This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100) lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).
What is the current status of trial NCT03773172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-01-31. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03773172?
The interventions under investigation include: Placebo (DRUG), MEDI6012 (DRUG).
Who is sponsoring clinical trial NCT03773172?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03773172's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI